| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology, and Genetics |
Departments of 1 Molecular Cell Biology and 2 Physics of Complex Systems, Weizmann Institute of Science, Rehovot, Israel and 3 Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, Maryland
Requests for reprints: Varda Rotter, Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel. Phone: 972-8-9344501; Fax: 972-8-9465265; E-mail: varda.rotter{at}weizmann.ac.il.
The difficulty to dissect a complex phenotype of established malignant cells to several critical transcriptional programs greatly impends our understanding of the malignant transformation. The genetic elements required to transform some primary human cells to a tumorigenic state were described in several recent studies. We took the advantage of the global genomic profiling approach and tried to go one step further in the dissection of the transformation network. We sought to identify the genetic signatures and key target genes, which underlie the genetic alterations in p53, Ras, INK4A locus, and telomerase, introduced in a stepwise manner into primary human fibroblasts. Here, we show that these are the minimally required genetic alterations for sarcomagenesis in vivo. A genome-wide expression profiling identified distinct genetic signatures corresponding to the genetic alterations listed above. Most importantly, unique transformation hallmarks, such as differentiation block, aberrant mitotic progression, increased angiogenesis, and invasiveness, were identified and coupled with genetic signatures assigned for the genetic alterations in the p53, INK4A locus, and H-Ras, respectively. Furthermore, a transcriptional program that defines the cellular response to p53 inactivation was an excellent predictor of metastasis development and bad prognosis in breast cancer patients. Deciphering these transformation fingerprints, which are affected by the most common oncogenic mutations, provides considerable insight into regulatory circuits controlling malignant transformation and will hopefully open new avenues for rational therapeutic decisions.
This article has been cited by other articles:
![]() |
F. Kosari, J. M. A. Munz, C. D. Savci-Heijink, C. Spiro, E. W. Klee, D. M. Kube, L. Tillmans, J. Slezak, R. J. Karnes, J. C. Cheville, et al. Identification of Prognostic Biomarkers for Prostate Cancer Clin. Cancer Res., March 15, 2008; 14(6): 1734 - 1743. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Yague, A. Arance, L. Kubitza, M. O'Hare, P. Jat, C. M. Ogilvie, I. R. Hart, C. F. Higgins, and S. Raguz Ability to Acquire Drug Resistance Arises Early during the Tumorigenesis Process Cancer Res., February 1, 2007; 67(3): 1130 - 1137. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |